We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

135 hedge funds and large institutions have $223M invested in Celldex Therapeutics in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 38 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 14

24% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 38

9% more capital invested

Capital invested by funds: $204M → $223M (+$18.6M)

5% more funds holding

Funds holding: 129 → 135 (+6)

0.14% more ownership

Funds ownership: 3.71% → 3.84% (+0.14%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

21% less call options, than puts

Call options by funds: $867K | Put options by funds: $1.1M

Holders
135
Holders Change
+6
Holders Change %
+4.65%
% of All Funds
3.06%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
21
Increased
47
Reduced
38
Closed
14
Calls
$867K
Puts
$1.1M
Net Calls
-$230K
Net Calls Change
-$297K

Top Buyers

1
CWAM
Columbia Wanger Asset Management
Illinois
+$15.9M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$4.35M
3
PAM
Panagora Asset Management
Massachusetts
+$2.81M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.47M
5
Millennium Management
Millennium Management
New York
+$1.15M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.78M
2
Citadel Advisors
Citadel Advisors
Florida
-$2.6M
3
AC
Ascend Capital
California
-$1.13M
4
AG
Artal Group
Luxembourg
-$927K
5
Deutsche Bank
Deutsche Bank
Germany
-$806K
Name Holding Trade Value Shares
Change 		Change in
Stake
ASN
126
Advisory Services Network
Georgia
$1K – – –
LTFS
127
Ladenburg Thalmann Financial Services
Florida
$1K – – –
SIC
128
Salem Investment Counselors
North Carolina
$1K – – –
FWM
129
Focused Wealth Management
New York
$1K +$985 +23 New
MAM
130
Meeder Asset Management
Ohio
$1K +$1.03K +24 New
II
131
Inspire Investing
Idaho
$1K +$1.2K +28 New
Northwestern Mutual Wealth Management
132
Northwestern Mutual Wealth Management
Wisconsin
$1K +$1.41K +33 New
ECM
133
Estabrook Capital Management
New York
$307 – – –
Renaissance Technologies
134
Renaissance Technologies
New York
– -$575K -13,414 Closed
FCM
135
Frontier Capital Management
Massachusetts
– -$498K -11,609 Closed
BG
136
Bellevue Group
Switzerland
– -$458K -10,667 Closed
NFA
137
Nationwide Fund Advisors
Ohio
– -$320K -7,450 Closed
BCM
138
BlueCrest Capital Management
Jersey
– -$259K -6,029 Closed
DTL
139
Dynamic Technology Lab
Singapore
– -$242K -5,637 Closed
Canada Pension Plan Investment Board
140
Canada Pension Plan Investment Board
Ontario, Canada
– -$218K -5,080 Closed
NPC
141
National Planning Corporation
California
– -$167K -3,900 Closed
VF
142
Virtu Financial
New York
– -$100K -2,332 Closed
PCM
143
Prelude Capital Management
New York
– -$52K -1,220 Closed
PP
144
Paloma Partners
Connecticut
– -$45K -1,057 Closed
FCH
145
Freestone Capital Holdings
Washington
– -$29K -670 Closed
NFG
146
Next Financial Group
Texas
– -$12K -267 Closed
PHK
147
Point72 Hong Kong
Hong Kong
– -$2K -36 Closed
MSA
148
Marino Stram & Associates
Massachusetts
– +$471 +11 New
2 3 4 5
6

CLDX Hedge Fund Activity: Q4 2017 in Review

135 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2017, worth a combined $223M — up 9.1% from $204M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new CLDX positions and 14 closed out — a net gain of 7 holders — while 47 added to existing stakes and 38 trimmed.

The largest buyer was Columbia Wanger Asset Management, adding an estimated $15.9M. The largest seller was Fidelity Investments, cutting an estimated $3.78M.

  • 135 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2017, up from 129 in Q3 2017.
  • Funds reported $223M of Celldex Therapeutics stock for Q4 2017, up 9.1% quarter-over-quarter.
  • 21 funds opened new Celldex Therapeutics positions in Q4 2017 and 14 closed out, a net change of +7 holders.
  • The largest Celldex Therapeutics buyer in Q4 2017 was Columbia Wanger Asset Management, an estimated $15.9M added.
  • The largest Celldex Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $3.78M sold.

Based on aggregated 13F filings for Q4 2017.